tirzepatide's dedicated SURPASS-CVOT cardiovascular outcomes trial is ongoing
These patients may require combination therapy with basal insulin or other agents targeting different pathophysiological mechanisms
Zambrano, M
Nausea, diarrhea, and decreased appetite occur most frequently but typically improve within the first few weeks
The most frequently reported adverse reactions (1% or more and twice rate of placebo) were ECG voltage criteria for ventricular hypertrophy, tic, vomiting, psychomotor hyperactivity, insomnia, decreased appetite and rash [2 instances for each adverse reaction, i.e., 2/218 (1%)]
If you are struggling to hit protein at all on a given day, the bowl is not the only lever